Assay ID | Title | Year | Journal | Article |
AID689515 | Downregulation of G6p mRNA expression in KK-Ay mouse liver at 10 mg/kg/day, po administered for 14 days by RT-PCR analysis | 2012 | ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
| RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists. |
AID689359 | Toxicity in male Sprague-Dawley rat assessed as change in water intake at 30 mg/kg/day, po for 28 days relative to vehicle-treated control | 2012 | ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
| RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists. |
AID689372 | Toxicity in KK-Ay mouse assessed as increase in body weight at 10 mg/kg/day, po administered for 14 days relative to vehicle-treated control | 2012 | ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
| RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists. |
AID730286 | Partial agonist activity at mouse RXRalpha expressed in COS1 cells by luciferase reporter gene assay relative to bexarotene | 2013 | Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
| Mechanism of retinoid X receptor partial agonistic action of 1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-1H-benzotriazole-5-carboxylic acid and structural development to increase potency. |
AID1633895 | Toxicity in fertilized zebra fish embryos assessed as survival rate at 1000 nM incubated for 120 hrs post fertilization by microscopic method relative to untreated control (Rvb = 100%) | 2019 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 29, Issue:15
| 3H-Imidazo[4,5-b]pyridine-6-carboxylic acid derivatives as rexinoids with reduced teratogenicity. |
AID689353 | Drug level in ICR mouse serum at 30 mg/kg, po | 2012 | ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
| RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists. |
AID1633901 | Aqueous solubility in pH 7.4 PBS buffer at 1 mM after 6 hrs by HPLC analysis | 2019 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 29, Issue:15
| 3H-Imidazo[4,5-b]pyridine-6-carboxylic acid derivatives as rexinoids with reduced teratogenicity. |
AID689361 | Toxicity in male Sprague-Dawley rat assessed as change in food intake at 30 mg/kg/day, po for 28 days relative to vehicle-treated control | 2012 | ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
| RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists. |
AID689516 | Downregulation of Pck mRNA expression in KK-Ay mouse liver at 10 mg/kg/day, po administered for 14 days by RT-PCR analysis | 2012 | ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
| RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists. |
AID689360 | Toxicity in female Sprague-Dawley rat assessed as change in water intake at 30 mg/kg/day, po for 28 days relative to vehicle-treated control | 2012 | ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
| RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists. |
AID730302 | Transactivation of RXRalpha (unknown origin) expressed in COS1 cells at 10 uM after 18 hrs by luciferase reporter gene assay relative to bexarotene | 2013 | Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
| Mechanism of retinoid X receptor partial agonistic action of 1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-1H-benzotriazole-5-carboxylic acid and structural development to increase potency. |
AID689341 | Partial agonist activity at RXRalpha expressed in human Cos1 cells after 18 hrs by SEAP reporter gene assay | 2012 | ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
| RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists. |
AID1633900 | Agonist activity at human RXRalpha expressed in African green monkey COS1 cells harboring CRBP2-tk-luc reporter incubated for 18 hrs by steady-glo luciferase reporter gene assay relative to control | 2019 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 29, Issue:15
| 3H-Imidazo[4,5-b]pyridine-6-carboxylic acid derivatives as rexinoids with reduced teratogenicity. |
AID689365 | Toxicity in female Sprague-Dawley rat assessed as change in serum constituents at 30 mg/kg/day, po for 28 days relative to vehicle-treated control | 2012 | ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
| RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists. |
AID1633894 | Toxicity in fertilized zebra fish embryos assessed as survival rate at 300 nM incubated for 120 hrs post fertilization by microscopic method relative to untreated control (Rvb = 100%) | 2019 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 29, Issue:15
| 3H-Imidazo[4,5-b]pyridine-6-carboxylic acid derivatives as rexinoids with reduced teratogenicity. |
AID689369 | Antidiabetic activity in diabetic, obese KK-Ay mouse assessed as reduction in HbA1c level at 10 mg/kg/day, po administered for 14 days relative to vehicle-treated control | 2012 | ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
| RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists. |
AID689352 | Agonist activity at LXRalpha/RXRalpha expressed in human Cos1 cells after 18 hrs by SEAP reporter gene assay | 2012 | ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
| RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists. |
AID689356 | Toxicity in ICR mouse assessed as increase in serum triglyceride level at 30 mg/kg/day, po for 7 days relative to vehicle-treated control | 2012 | ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
| RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists. |
AID689349 | Agonist activity at PPARgamma expressed in human Cos1 cells after 18 hrs by SEAP reporter gene assay | 2012 | ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
| RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists. |
AID1633896 | Toxicity in fertilized zebra fish embryo assessed as teratogenic effect by measuring malformation of spine curvature and head enlargement at 100 nM after 120 hrs post fertilization by microscopic method relative to control | 2019 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 29, Issue:15
| 3H-Imidazo[4,5-b]pyridine-6-carboxylic acid derivatives as rexinoids with reduced teratogenicity. |
AID689520 | Upregulation of Srebp1c mRNA expression in KK-Ay mouse liver at 10 mg/kg/day, po administered for 14 days by RT-PCR analysis | 2012 | ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
| RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists. |
AID1633898 | Toxicity in fertilized zebra fish embryo assessed as teratogenic effect by measuring malformation of spine curvature and head enlargement at 1000 nM after 120 hrs post fertilization by microscopic method relative to control | 2019 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 29, Issue:15
| 3H-Imidazo[4,5-b]pyridine-6-carboxylic acid derivatives as rexinoids with reduced teratogenicity. |
AID689351 | Agonist activity at LXRalpha expressed in human Cos1 cells after 18 hrs by SEAP reporter gene assay | 2012 | ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
| RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists. |
AID689371 | Antidiabetic activity in diabetic, obese KK-Ay mouse assessed as increase in adiponectin level at 10 mg/kg/day, po administered for 14 days by oral glucose tolerance test | 2012 | ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
| RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists. |
AID1633888 | Toxicity in fertilized zebra fish embryos assessed as hatching rate at 100 nM incubated for 120 hrs post fertilization by microscopic method relative to untreated control (Rvb = 100%) | 2019 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 29, Issue:15
| 3H-Imidazo[4,5-b]pyridine-6-carboxylic acid derivatives as rexinoids with reduced teratogenicity. |
AID689362 | Toxicity in female Sprague-Dawley rat assessed as change in food intake at 30 mg/kg/day, po for 28 days relative to vehicle-treated control | 2012 | ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
| RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists. |
AID1633890 | Toxicity in fertilized zebra fish embryos assessed as hatching rate at 300 nM incubated for 120 hrs post fertilization by microscopic method relative to untreated control (Rvb = 100%) | 2019 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 29, Issue:15
| 3H-Imidazo[4,5-b]pyridine-6-carboxylic acid derivatives as rexinoids with reduced teratogenicity. |
AID730297 | Partial agonist activity at human RXRalpha expressed in Escherichia coli BL21AI assessed as recruitment of fluorescent-labeled coactivator D22 at 10 uM after 1 hr by fluorescence polarization assay | 2013 | Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
| Mechanism of retinoid X receptor partial agonistic action of 1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-1H-benzotriazole-5-carboxylic acid and structural development to increase potency. |
AID730300 | Transactivation of RXRalpha (unknown origin) expressed in COS1 cells at 0.1 uM after 18 hrs by luciferase reporter gene assay relative to bexarotene | 2013 | Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
| Mechanism of retinoid X receptor partial agonistic action of 1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-1H-benzotriazole-5-carboxylic acid and structural development to increase potency. |
AID689363 | Toxicity in male Sprague-Dawley rat assessed as enlarged testes at 30 mg/kg/day, po for 28 days relative to vehicle-treated control | 2012 | ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
| RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists. |
AID689347 | Transactivation of RARbeta expressed in human Cos1 cells after 18 hrs by SEAP reporter gene assay | 2012 | ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
| RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists. |
AID689513 | Upregulation of Slc2a1 mRNA expression in KK-Ay mouse liver at 10 mg/kg/day, po administered for 14 days by RT-PCR analysis | 2012 | ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
| RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists. |
AID689354 | Toxicity in ICR mouse assessed as increase in body weight at 30 mg/kg/day, po for 7 days relative to vehicle-treated control | 2012 | ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
| RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists. |
AID689355 | Toxicity in ICR mouse assessed as increase in liver weight at 30 mg/kg/day, po for 7 days relative to vehicle-treated control | 2012 | ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
| RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists. |
AID689357 | Toxicity in male Sprague-Dawley rat assessed as change in body weight at 30 mg/kg/day, po for 28 days relative to vehicle-treated control | 2012 | ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
| RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists. |
AID689348 | Transactivation of RARgamma expressed in human Cos1 cells after 18 hrs by SEAP reporter gene assay | 2012 | ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
| RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists. |
AID689358 | Toxicity in female Sprague-Dawley rat assessed as change in body weight at 30 mg/kg/day, po for 28 days relative to vehicle-treated control | 2012 | ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
| RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists. |
AID730285 | Partial agonist activity at human RXRalpha by luciferase reporter gene assay | 2013 | Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
| Mechanism of retinoid X receptor partial agonistic action of 1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-1H-benzotriazole-5-carboxylic acid and structural development to increase potency. |
AID689343 | Partial agonist activity at RXRbeta expressed in human Cos1 cells after 18 hrs by SEAP reporter gene assay | 2012 | ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
| RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists. |
AID689374 | Toxicity in KK-Ay mouse assessed as increase in serum triglyceride level at 10 mg/kg/day, po administered for 14 days relative to vehicle-treated control | 2012 | ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
| RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists. |
AID730301 | Transactivation of RXRalpha (unknown origin) expressed in COS1 cells at 1 uM after 18 hrs by luciferase reporter gene assay relative to bexarotene | 2013 | Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
| Mechanism of retinoid X receptor partial agonistic action of 1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-1H-benzotriazole-5-carboxylic acid and structural development to increase potency. |
AID689344 | Partial agonist activity at RXRgamma expressed in human Cos1 cells after 18 hrs by SEAP reporter gene assay | 2012 | ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
| RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists. |
AID1633897 | Toxicity in fertilized zebra fish embryo assessed as teratogenic effect by measuring malformation of spine curvature and head enlargement at 300 nM after 120 hrs post fertilization by microscopic method relative to control | 2019 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 29, Issue:15
| 3H-Imidazo[4,5-b]pyridine-6-carboxylic acid derivatives as rexinoids with reduced teratogenicity. |
AID689345 | Partial antagonist activity at RXRalpha expressed in human Cos1 cells assessed as reduction in LGD1069-induced luciferase activity after 18 hrs by SEAP reporter gene assay | 2012 | ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
| RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists. |
AID689517 | Upregulation of Gck mRNA expression in KK-Ay mouse liver at 10 mg/kg/day, po administered for 14 days by RT-PCR analysis | 2012 | ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
| RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists. |
AID689518 | Upregulation of Fasn mRNA expression in KK-Ay mouse liver at 10 mg/kg/day, po administered for 14 days by RT-PCR analysis | 2012 | ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
| RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists. |
AID1633899 | Agonist activity at human RXRalpha expressed in African green monkey COS1 cells harboring CRBP2-tk-luc reporter incubated for 18 hrs by steady-glo luciferase reporter gene assay | 2019 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 29, Issue:15
| 3H-Imidazo[4,5-b]pyridine-6-carboxylic acid derivatives as rexinoids with reduced teratogenicity. |
AID689346 | Transactivation of RARalpha expressed in human Cos1 cells after 18 hrs by SEAP reporter gene assay | 2012 | ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
| RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists. |
AID689375 | Toxicity in KK-Ay mouse assessed as increase in total cholesterol level at 10 mg/kg/day, po administered for 14 days relative to vehicle-treated control | 2012 | ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
| RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists. |
AID730298 | Partial agonist activity at RXRalpha (unknown origin) expressed in COS1 cells after 18 hrs by luciferase reporter gene assay relative to bexarotene | 2013 | Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
| Mechanism of retinoid X receptor partial agonistic action of 1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-1H-benzotriazole-5-carboxylic acid and structural development to increase potency. |
AID689370 | Antidiabetic activity in diabetic, obese KK-Ay mouse assessed as increase in glucose tolerance at 10 mg/kg/day, po administered for 14 days by oral glucose tolerance test | 2012 | ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
| RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists. |
AID730299 | Partial agonist activity at RXRalpha (unknown origin) expressed in COS1 cells after 18 hrs by luciferase reporter gene assay | 2013 | Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
| Mechanism of retinoid X receptor partial agonistic action of 1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-1H-benzotriazole-5-carboxylic acid and structural development to increase potency. |
AID689342 | Partial agonist activity at RXRalpha expressed in human Cos1 cells after 18 hrs by SEAP reporter gene assay relative to 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethenyl]benzoic acid | 2012 | ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
| RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists. |
AID689514 | Upregulation of Slc2a2 mRNA expression in KK-Ay mouse liver at 10 mg/kg/day, po administered for 14 days by RT-PCR analysis | 2012 | ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
| RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists. |
AID689373 | Toxicity in KK-Ay mouse assessed as increase in liver weight at 10 mg/kg/day, po administered for 14 days relative to vehicle-treated control | 2012 | ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
| RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists. |
AID689376 | Upregulation of Irs1 mRNA expression in KK-Ay mouse liver at 10 mg/kg/day, po administered for 14 days by RT-PCR analysis | 2012 | ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
| RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists. |
AID689368 | Antidiabetic activity in diabetic, obese KK-Ay mouse assessed as reduction in serum insulin level at 10 mg/kg/day, po administered for 14 days relative to vehicle-treated control | 2012 | ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
| RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists. |
AID689364 | Toxicity in male Sprague-Dawley rat assessed as change in serum constituents at 30 mg/kg/day, po for 28 days relative to vehicle-treated control | 2012 | ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
| RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists. |
AID689512 | Upregulation of Irs2 mRNA expression in KK-Ay mouse liver at 10 mg/kg/day, po administered for 14 days by RT-PCR analysis | 2012 | ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
| RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists. |
AID1633891 | Toxicity in fertilized zebra fish embryos assessed as hatching rate at 1000 nM incubated for 120 hrs post fertilization by microscopic method relative to untreated control (Rvb = 100%) | 2019 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 29, Issue:15
| 3H-Imidazo[4,5-b]pyridine-6-carboxylic acid derivatives as rexinoids with reduced teratogenicity. |
AID1633892 | Toxicity in fertilized zebra fish embryos assessed as survival rate at 100 nM incubated for 120 hrs post fertilization by microscopic method relative to untreated control (Rvb = 100%) | 2019 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 29, Issue:15
| 3H-Imidazo[4,5-b]pyridine-6-carboxylic acid derivatives as rexinoids with reduced teratogenicity. |
AID689367 | Antidiabetic activity in diabetic, obese KK-Ay mouse assessed as reduction in blood glucose level at 10 mg/kg/day, po administered for 14 days relative to vehicle-treated control | 2012 | ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
| RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists. |
AID689519 | Upregulation of Scd1 mRNA expression in KK-Ay mouse liver at 10 mg/kg/day, po administered for 14 days by RT-PCR analysis | 2012 | ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
| RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists. |
AID689350 | Agonist activity at PPARgamma/RXRalpha expressed in human Cos1 cells after 18 hrs by SEAP reporter gene assay | 2012 | ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
| RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |